New Study Shows the Rate of Drug Approvals Lower than Previously Reported

WASHINGTON--(BUSINESS WIRE)--Biotechnology Industry Organization (BIO) Industry Analysis and BioMedTracker (BMT) announced results of a study today that shows the overall success rate for drugs moving through clinical trials to FDA approval from late 2003 to the end of 2010 is near one in 10. Previous reports, taken from earlier years, showed the rate of drug approvals is one in five to one in six. The study’s release coincides with the 13^th Annual BIO CEO & Investor Conference, February 14-15 in New York City at the Waldorf=Astoria. Full details on the study will be posted to the BIO Industry Analysis site on Tuesday, February 15 immediately following a panel session highlighting results of the study.

“Knowing more about the magnitude of risk can lead to smarter drug development as well as smarter investing.”

“This groundbreaking study highlights the depth and breadth of risk inherent in the drug development process more comprehensively than any other previous study,” said Alan Eisenberg, Executive Vice President of Emerging Companies and Business Development at BIO. “Knowing more about the magnitude of risk can lead to smarter drug development as well as smarter investing.”

The study builds on the findings from previous studies and uses a broader, deeper, and larger sample than previous reviews of clinical trials and approvals data using the BioMedTracker (BMT) proprietary database of 4,500 drugs and over 8,000 unique development paths.

"Having an up-to-date and detailed picture of clinical success rates, and ultimately how likely a drug is to be approved, is vital to our clients when making investment and business decisions. We believe that this study provides the market with an accurate and comprehensive picture of the relative difficulty of achieving product approval in the US," remarked Michael Hay, Senior Biotechnology Analyst at BMT. "Strikingly, oncology drugs have the toughest time making their way through the clinic, despite cancer being the most closely studied area in drug development. We are very pleased to be able to offer this analysis and provide an in-depth look at the issues facing the industry that lead to these lower rates."

Using clinical trial data from the past seven years, the analysis examines the most recent probability of success by treatment type, phase of development and therapeutic area. Before new therapies hit the market, they have to pass a number of hurdles – meeting regulatory thresholds for efficacy and safety as well as maintaining a competitive internal corporate profitability and marketability profile.

Key findings from the study include:

• Overall success rates from Phase I to FDA approval is nearly 9%. This number is comprised of lead and secondary indications. When separated, lead indications have close to a one in seven rate of approval and secondary indications have a rate of one in 30.
• Clinical Trials that address secondary Indications for drugs tend to be far less successful on average. This was seen in all phases of clinical development as well as in all disease areas.
• The study also shows that large molecule drugs are twice as successful in gaining approval than small molecule drugs.

The BMT/BIO study examines the clinical Phase status of these development paths as of year-end 2003 through year-end 2010, which accounts for more than 59,000 data points. The study determines the percentage of drugs that advance to the next Phase of development versus those that are suspended and therefore the likelihood of a drug ultimately being approved by the FDA. The data spans all companies (Big Pharma and biotechnology, both public and private) conducting development on therapeutics for approval in the U.S.

The BMT/BIO analysis includes breakdowns by indication, disease group, size of company, molecule type, route of administration, New Molecular Entity (NME) versus Biologic versus non-NME. The data encompasses the most recent data available during a time in which FDA requirements for approval have been in flux. Included in the analysis is an in-depth look at FDA decisions and approval rates by FDA review number.

Study results will be discussed in a panel session - Trial and Error: Breaking Down Clinical Trial Success Rates - at the BIO CEO & Investor Conference. Speakers on the panel include:

• David Strupp, Managing Director, Rodman & Renshaw, LLC (moderator)
• Ted Buckley, PhD, Chief Economist, Bloomberg
• Lawrence T. Friedhoff, MD, PhD, FACP, CEO of Pharmaceutical Special Projects Group, LLC
• Michael Hay, Senior Biotechnology Analyst, Sagient Research Systems
• David Thomas, Director, Industry Research & Analysis, Biotechnology Industry Organization (BIO)

The 13^th Annual BIO CEO & Investor Conference provides a forum for institutional investors, research analysts and senior industry executives to discuss investment trends, attend company presentations, conduct one-on-one meetings, and learn about investment opportunities within the biotechnology industry. This event is the world’s largest independent investor conference focused on publicly-traded biotechnology companies.

Media registration is complimentary for qualified investors and credentialed members of the media.

About BIO

BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIO produces BIOtech Now, an online portal and monthly newsletter chronicling “innovations transforming our world.” Subscribe to BIOtech Now.

About BioMedTracker

BioMedTracker (www.biomedtracker.com) is an institutional research service that identifies investment opportunities in the biotech and pharmaceutical industry by assessing the relative strength of companies’ clinical drug pipelines and by highlighting potential future catalysts that could dramatically impact those pipelines. Clients from the pharmaceutical, biotech, and investment industries rely on BioMedTracker for its insight on the likelihood of approval, commercial potential, and future data and regulatory catalysts for drugs within the competitive landscape of every important disease and indication. Over the last several years, BioMedTracker has become the leader in providing objective information alongside subjective clinical assessments on pipeline drugs worldwide.